The Enhanced Games: Tech’s Performance-Enhancing Showcase Faces $60 Million Deficit

In May, I traveled to Las Vegas for the Enhanced Games — a one-of-a-kind sports event that permits athletes to compete using performance-enhancing drugs typically banned in professional sports. Often dubbed the “steroid Olympics,” the event was organized by a telehealth company backed by notable figures like Peter Thiel and staffed with professionals from the crypto, AI, and biotech fields.

The results of the event were rather disappointing. Marketed by its founders as a revolutionary spectacle set to transform organized sports, the games produced few exhilarating moments. A mere single world record was achieved, and it came in swimming, a sport known for its frequent record-breaking.

Now it’s clear that the games not only failed to meet competitive standards but also fell short in terms of commercial success. This week, the Enhanced Group, the company behind the event, disclosed its second-quarter earnings, revealing an alarming net loss of nearly $62 million, largely due to the expenses incurred from hosting the games.

Founded in 2023, the Enhanced Group went public earlier this year with a valuation of $1.2 billion. It offers personalized health solutions through a digital telehealth platform, providing FDA-approved treatments such as peptides, testosterone injections, GLP-1s for weight loss, and similar products.

According to the Q2 earnings report, the company brought in $17.7 million last quarter, mostly from sponsorships linked to the games rather than its core telehealth services. There remains ambiguity about the performance of that core business. The report raises concerns about previous claims made by Enhanced executives regarding the games becoming an annual event (the company will need to either markedly increase revenue or face significant annual losses).

Enhanced may already be signaling a strategic pivot. The report also mentions the recent launch of a new online series, Enhanced Breakers, which the firm states “operates at a fraction of the cost of a full Games event,” while still enabling “athletes to compete, audiences to engage, sponsors to stay interested, and performance medicine to be showcased worldwide throughout the year.”

Despite the hurdles faced by Enhanced, the industry surrounding it is on the ascent. The peptide market is flourishing, boosted by a recent FDA decision during the Trump administration to reclassify several substances that once occupied a legal gray area. Although this governmental support doesn’t immediately authorize the widespread selling of these substances — as additional review is required — it shows a favorable inclination towards deregulating the sector.

Leading the FDA’s parent agency, the U.S. Department of Health and Human Services, is Robert F. Kennedy Jr., recognized for his unorthodox health perspectives. Medical professionals, both inside and outside the government, have condemned Kennedy’s views as hazardous — yet this backlash has not stalled the sector’s growth.

Silicon Valley continues to be a vibrant hub for peptide startups, with companies like Superpower and Noho Labs leveraging the tech industry’s obsession with biohacking and trendy health supplements. The rapid expansion of this sector is outpacing current regulations, leaving state governments scrambling to establish effective regulatory frameworks.